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ABSTRACT 
Despite promising advances in the field and highly effective first-line treatment, an estimated 
9.6 million people are still infected with tuberculosis. Innovative methods are required to 
effectively transition the growing number of compounds into novel combination regimens. 
However, progression of compounds into patients occurs despite the lack of clear 
understanding of the pharmacokinetic-pharmacodynamic relationships. The PreDiCT-TB 
consortium was established in response to the existing gaps in tuberculosis drug 
development. The aim of the consortium is to develop new preclinical tools in concert with 
an in silico model-based approach, grounded in pharmacokinetic-pharmacodynamic 
principles. This paper highlights the potential impact of such an integrated framework on 
various stages in tuberculosis drug development and on the dose rationale for drug 
combinations. 
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Introduction 
The development of new combination therapies for tuberculosis (TB) is lengthy and costly (1). 
Despite promising advances in the field, innovative methods are still needed to effectively 
transition the growing number of compounds into novel combination regimens. Among other 
things it is essential to shorten current treatment and tackle multidrug resistant tuberculosis.  
 
Shift in paradigm in tuberculosis drug development: reality or fiction? 
The disappointing results from all recent Phase 3 trials (2-5) clearly demonstrate that a shift 
in paradigm is needed in TB drug development. Insufficient efficacy is the main cause for 
failures in clinical drug development (6, 7). Achieving efficacious drug exposure at the site of 
action is imperative for producing the desired response, i.e., reducing or preventing relapses. 
Nevertheless, the decision making process in Phase 2 or 3 trials has remained empirical and 
recent development programs have progressed with limited pharmacokinetic-
pharmacodynamic (PKPD) knowledge to support the dose selection and study design. Clearly, 
dose selection must be based on evaluation of the pharmacokinetic properties and 
concentration-effect (PKPD) relationship of each drug, rather than by trial and error. Such 
concerns are also applicable to the most common approach, i.e., the use of currently 
approved doses for the background standard of care treatment.  
The challenges above are compounded by another major bottleneck in the development 
pathway in that current regulatory guidelines support the need for a long and often poorly 
informative range of studies. The rationale for testing different doses, regimens and sequence 
of add-on drug of each potential combination is clearly inefficient (8). At least six years (an 
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estimated one year for Phase 1, two years for Phase 2, and three years for Phase 3) are 
required to develop one new antibiotic (1), whereas more than two decades (4x6 years) 
would be needed for the development and approval of a completely novel regimen consisting 
of four new antibiotics through successive trials (1). This paper focuses on how an integrated 
PKPD/disease modelling and simulation framework, also known as model-informed drug 
discovery and development (MID3), could accelerate the development of novel combination 
therapies and highlight the potential impact of such framework to inform more robust 
decision making in TB drug development. 
Historically, the approval of current first short-course therapy for TB was preceded by 
sequential testing of promising candidates in preclinical experiments, which were then 
followed by clinical studies under the sponsorship of the British Medical Research Council 
(BMRC) in the 1970s and 1980s (9). These drugs were approved based on the traditional 
paradigm in drug development in which the progression of candidates depended on a 
sequential decision-making process. i.e., each phase is considered as discrete steps that are 
successfully completed as soon as pre-defined targets or criteria are met. This approach, 
however, does not provide the flexibility that is required to rapidly and effectively assess 
multiple new combination regimens in a single development programme. Yet, new anti-TB 
drugs or combinations are still assessed according to the same linear pathway before moving 
to large trials in which the new drug is added to or used as substitution to one of the drugs in 
the standard regimen (10, 11).  Most alarmingly is the lack of a strong scientific basis for the 
selection of doses and dosing regimens for one of the major poverty-related diseases. 
  
PreDiCT-TB: a quantitative framework for tuberculosis drug development 
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A robust quantitative framework is required to integrate data and facilitate effective 
translation of preclinical findings to humans. To that purpose PreDiCT-TB, an Innovative 
Medicines Initiative (IMI)-funded project consisting of pharmaceutical R&D and academic 
partners, has proposed the development of model-informed approaches to address some of 
the existing gaps in TB drug development. In particular, attention is given to opportunities for 
improved evidence generation as well as evidence synthesis for the evaluation of new, more 
effective combinations of treatments.  PKPD/disease modelling and simulation have been 
established as powerful tools for the characterisation of efficacy and safety in other 
therapeutic areas (12, 13). Its impact on therapeutics and drug development has been 
reviewed extensively (14). A formal modelling framework that integrates data arising from 
novel or existing preclinical models and historical clinical studies is envisaged to inform 
decision-making at different stages of development, i.e., optimisation of experimental 
protocols, sampling schemes and design the subsequent studies or termination of the project 
(15). Most importantly it enables comprehensive evaluation of the dose rationale (16).   
Within PreDiCT-TB, a set of carefully selected anti-TB drugs (licensed and unlicensed) are 
being evaluated in standard and novel preclinical models. In parallel, a comprehensive 
database consisting of individual patient data from historical clinical trials will be established 
for use as a reference for evaluating the performance of multiple anti-TB drug regimens, as 
assessed by preclinical models. These results will be used to refine experimental protocol 
conditions and identify experimental designs that are most informative, i.e., provide evidence 
of the underlying concentration-effect relationships or support the translation of drug effects 
in humans (17). Both preclinical and clinical data will then contribute to the development and 
validation of a PKPD/disease modelling and simulation framework, which is intended to 
support the progression of candidate molecules into clinical development. Among the key 
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deliverables of the consortium are the evaluation of (adaptive) study designs and translational 
research platforms for novel combination therapies for TB (Figure 1 and 2). An overview of 
current recommendations for implementation of a model-informed approach as envisaged 
by PreDiCT-TB is presented in Error! Reference source not found.. 
 
Evidence generation and evidence synthesis at candidate selection  
The availability of preclinical models that reflect key human pathological features of 
tuberculosis infection would be a valuable tool for translating pharmacokinetic-
pharmacodynamic (PKPD) concepts, offering a strong rationale for clinical trial designs (19, 
20). If designed properly, such experiments could also facilitate the characterisation of PKPD 
relationships of drugs in combination therapies, providing insight into exposure levels that 
correspond with optimal effect. Based on this approach, pre-clinical findings should form the 
basis for dose selection in humans and support the design of subsequent clinical studies (19).   
TB has seen many exciting advances in preclinical research (21, 22). In vitro and animal models 
are becoming more sophisticated and have enabled us to generate more insight regarding 
the immunopathology of the disease and the interaction between various Mycobacterium 
tuberculosis (Mtb) subpopulations (23). However, given major differences in TB susceptibility 
and histopathology that currently exist between animal model, it is unlikely that a single 
experimental system will become available that could fully mimic the infection process in 
humans. In addition, large variability is observed in in vivo efficacy studies depending on the 
choice of Mtb strain (24).  In most cases, these experiments rely on limited information about 
drug combinations, range of doses or dosing intervals. Consequently, translation of preclinical 
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data to inform suitable combinations and appropriate dosing regimens in clinical trials is 
anything but accurate. 
PKPD/disease models can be developed to systematically characterise the differences in 
disease condition and evaluate the impact of combination therapies on the PKPD relationship 
of backbone treatment in various animal models. It can be anticipated that the use of such 
models may allow 1) the refinement of experimental protocols, consequently reducing the 
sample size needed in preclinical studies without compromising the precision of information 
derived from the experiment, 2) inform prioritization of the best drug combinations to be 
tested in clinical development, and 3) systematically evaluate the performance of various 
preclinical models against available human data. It should be emphasised that even if 
shortcomings were to be found in the translation of findings, the use of a model-informed 
approach does represent a considerable improvement in terms of the 3 Rs (reduction, 
replacement and refinement). 
 
Evidence generation and evidence synthesis during clinical drug development   
Once the best predictive preclinical models are identified, clinical trial simulations (CTS) can 
be harnessed to evaluate an unlimited number of experimental scenarios (i.e. drug 
combinations, dose selection, sampling times, and sample sizes) on a systematic manner to 
identify the best clinical study design. For example, CTS has been successfully used to support 
selection of the dose range of antibiotics in  phase II/III studies by integrating data on the 
distribution of MICs for clinical isolates with the PD target(s) developed from animal models 
of infection and pharmacokinetic characteristics of the compound (25). By contrast, Phase 2 
studies have often ignored pharmacokinetic variability and other sources of variation in 
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treatment response in the target patient population, which need to be accounted for when 
exploring the dose–exposure-response relationship. The impact of CTS during clinical 
development by means of providing stronger support for regulatory approval and labelling 
has been established in other therapeutic area (12, 26) and acknowledged by the regulatory 
agencies (27). Given that only a limited number of combinations can be tested in humans, it 
is crucial to harness methods that facilitate more robust study design and dose range 
selection prior to the start of the actual trial. If necessary, data from Phase 2a can be used 
prospectively to refine the PKPD/disease model and increase its performance to assess the 
best Phase 2b and 3 study protocol (i.e. patient population, dose, sample size, sampling time, 
treatment duration and drug combinations). Moreover, additional factors such as different 
compliance patterns and other co-morbidities can be included into the simulation scenarios 
when evaluating the dose rationale for antibiotics that are used in a chronic manner. 
Ultimately, this approach allows one to explore the implications of critical factors on 
treatment response and address critical questions regarding the experimental protocol 
before the actual study is conducted.  
Results from Phase 2 and 3 trials have been traditionally reported without linking treatment 
outcome with individual drug exposure. However, availability of such data could explain 
variability in response and hence provide insight into whether any unsuccessful trial outcome 
might be attributed to underexposure to the drugs, rather than the novel regimen truly being 
inferior to the standard of care. Considering the cost and burden of Phase 2 and 3 trials, the 
integration of pharmacokinetics to efficacy trials should become a mandatory component of 
clinical protocols. Model-informed designs can be implemented that require sparse 
pharmacokinetic sampling, yielding accurate and precise estimation drug exposure in 
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individual patients (28). A PKPD analysis can subsequently be performed to evaluate the 
relationship between drug exposure and clinical response. 
Another important aspect regarding the evaluation of clinical response is the lack of 
consensus regarding the relevance of different endpoints in clinical trials (e.g. colony forming 
unit count vs. time to positivity). The concurrent use of different measures and regimen has 
made the comparison of historical and modern clinical trials incredibly challenging (29). 
Rather than neglecting historical data, in silico models can be used to characterise the 
relationship between different measures of bacterial load (30). The availability of such models 
will enable researchers to utilize as much existing data as possible to inform decision-making 
in TB drug development in a more robust manner.  
 
Challenges for the implementation of a model-informed approach at candidate selection 
The success of the proposed model-informed approach depends on the availability of suitable 
experimental data for the development of robust in silico models. This requirement is not 
trivial, in that most experimental protocols may only provide insight into the underlying PKPD 
relationships.  These limitations are often determined by costs and time constraints. 
However, even when full PKPD relationships are  characterised, discrepancies between animal 
models still pose a major challenge in extrapolating model predictions into clinical doses. 
Difference in bacterial strain (e.g. H37Rv versus Erdman), pathology (e.g. absence versus 
presence of necrotic lesions) or treatment condition (e.g. onset and duration of treatment) 
can yield significantly different PKPD parameters and hence varying  predictions of the clinical 
dose.  
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Efforts are being made within PreDiCT-TB to overcome some of these challenges. The 
consortium has identified a range of in vitro and in vivo models and performed a range of 
experiments to compare the differences in PKPD relationship of various anti-TB regimens. 
Even though the current clinical regimens with isoniazid, rifampicin, ethambutol and 
pyrazinamide are not truly optimised, evidence of differences in the pharmacokinetics and 
pharmacodynamics of standard drugs  across experimental models will provide insight into 
the sensitivity and specificity of these models to detect bactericidal, bacteriostatic and 
sterilising activity of the compounds currently used in humans.  
 
Challenges for the implementation of a model-informed approach in clinical drug 
development 
Most of the known issues for the clinical development of anti-tuberculosis agents cannot be 
overcome by PreDiCT-TB alone.  First, variability in pharmacokinetics continues to be 
overlooked. Collection of individual drug exposure is not included as a standard procedure in 
clinical protocols and blood sampling may not even be feasible in high-burden countries 
where most Phase III TB trials are performed. In addition, even if individual PKPD data are 
collected, such as sputum conversion, information from single measurement at the time of 
relapse will be insufficient to allow the development of predictive models for the detection 
of relapse. In addition to further understanding of the underlying biological mechanisms of 
relapse, it is critical to obtain repeated microbiological data during treatment and follow up. 
From a drug development perspective, what seems to become clear from EBA studies is that 
information on early bactericidal activity may not be suitable descriptor of the processes 
associated with relapse.  Another important limitation of EBA studies is that PKPD relationship 
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based on drug levels in plasma may not describe tissue exposure. Similarly, viable colony 
forming unit count in sputum may not represent the whole Mtb population in the human 
lung.  
Despite such limitations, the opportunity to replace the empirical basis upon which doses are 
selected will represent an important advancement for therapeutics with novel anti-
tuberculosis drugs. Last but not least, the consortium has managed to collate data from 
historical studies, creating a pool of individual patient level data which will facilitate the 
evaluation of the proposed framework for drug combinations. 
 
Consequences for regulatory approval   
Clearly, translation of the advancements obtained so far with regard to our increased 
understanding of the pathophysiology of infection by M. tuberculosis and improved 
knowledge of drug disposition and PKPD properties in tissues and target organs demands 
more than just the effective implementation of the MID3 concepts highlighted above. 
Regulatory acceptance and guidance needs to evolve as to ensure that lessons from this 
growing field are embedded into the drug approval process. A pro-active attitude by 
regulatory authorities has been observed in the last few years, in that a concept paper and 
new guidance have been issued, which focus on the development of entirely new regimens 
to treat TB, rather than focusing on single medicines.  
 
Recently, the European Medicines Agency (EMA) opened a consultation for updating the 
guideline on the evaluation of medicinal products indicated for treatment of bacterial 
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infections (31). Whereas the use of in vitro pharmacodynamic models such a the hollow fibre 
system have been endorsed for dose selection early on in the development programme, 
further insight from translational pharmacology and clinical trial simulations may play an 
important role in minimising the extent of dose- and/or regimen-finding clinical trials. 
Therefore, to be effective the new guidance should establish the mechanisms by which novel 
approaches for data generation and integration will be considered in future regulatory 
submissions. In this respect, a dialogue between public-private initiatives partnerships and 
regulatory agencies is timely and critical. Most importantly, regulators and experts need to 
weigh the importance of alternative endpoints and study designs for the approval of new 
medicines or combinations of medicines along with the role of biomarkers to predict the 
efficacy and effectiveness of alternative regimens during clinical development.  
 
Conclusion  
Improved efficiency in the development of drug combinations is urgently needed for the 
advancement of new treatments for tuberculosis. PreDiCT-TB has been created to overcome 
some of the critical gaps in early drug development and revolutionise the way evidence is 
generated and integrated to support the progression of candidate molecules into humans. 
The implementation of a model-informed approach to the design, analysis and interpretation 
of experimental data during preclinical phases of development will provide a more robust 
basis for the selection of suitable combinations and translate the appropriate dosing regimens 
for first time use in patients. In conjunction with clinical trial simulations, PreDiCT-TB expects 
to demonstrate the relevance of more informative clinical trial designs and offer regulatory 
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agencies a stronger scientific basis for the approval of treatments in a therapeutic area that 
has remained neglected for the last four decades. 
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Table and figure legends: 
 
Table 1. Overview of recommendations of how model-based approach can be used to address 
the current gaps in various stage of tuberculosis drug development. 
 
Figure 1. Diagram describing the individual components of the integrated PKPD/disease 
modelling and simulation framework. The disease model encompasses the natural growth 
and elimination rate of Mtb in the absence of antibiotics. The drug model characterise the PK 
and PKPD properties as well as any covariate effects on the disposition or pharmacodynamics 
of the drug. In addition to the disease and drug components, a trial model is used to assess 
treatment performance in the context of a clinical trial protocol. Among other factors, a trial 
model allows the assessment of the impact of  drop-outs, inclusion/exclusion criteria or 
compliance on trial outcome. Adapted from Gobburu and Lesko (18).  
 
Figure 2. A schematic overview of how PKPD/disease modelling and simulation framework 
can be applied to translate preclinical findings and identify the appropriate doses and dosing 
regimens for first time use in patients from preclinical experiments. Assuming the availability 
of data supporting the characterisation of dose/exposure-response relationship in vitro and 
in vivo (left column), in silico models can be developed that characterise the pharmacokinetic 
and pharmacokinetic-pharmacodynamic properties of the drug combinations of interest 
(middle column). After correcting for the interspecies differences in physiology and/or 
physiochemical properties, parameter estimates can subsequently be used to either scale 
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preclinical findings to humans or to facilitate the translation of drug effects taking into 
account differences between experimental and clinical conditions. Clinical trial simulations 
can be performed to inform the range of doses of each antibiotic that is expected to yield 
exposure levels (shaded green area) that are associated with the desired effect (dashed line) 
in preclinical experiments (right column). 
  
 
